Pharma companies often lack knowledge of the coverage landscape in drug categories dominated by low-cost generics. https://ow.ly/h10g50Su6rG In this case study, we see how one women’s health pharmaceutical company used MMIT’s solutions to evaluate access for its brand and drive new prescriptions. #Pharma #PharmaCompany #WomensHealth #MarketAccess
MMIT (Managed Markets Insight & Technology)’s Post
More Relevant Posts
-
Ready to dive into #MarketAccess planning for your medical benefit drug? Our primer is your practical guide, leading you through every step, from predicting uptake and tracking policies/pathways to payer contracting and provider engagement. Download the ebook now to discover the five crucial steps your organization should take to establish a firm foundation for your commercialization journey: https://ow.ly/CO5e50Sphlx. #MedicalBenefitTherapy #MedicalBenefitTherapies #CommercializationStrategy #HCPs
-
According to new research from MMIT and The Dedham Group, 73% of pharma companies are using real-world data for purposes beyond #MarketAccess. Learn more about what’s driving this change and the four key points in this breakdown of our survey results. https://ow.ly/GMMv50RZ3t0
-
MMIT's Directory of Health Plans helps organizations understand payer market share with the industry standard of enrollment and affiliation information. Learn more about the Directory of Health Plans: https://ow.ly/58UX50Q9Go2.
-
New in today’s Health Plan Weekly: Experts challenge spector of ACA enrollment fraud, Aetna wins big in Star Ratings redo, FTC raises eyebrows over latest PBM move, and more top stories. https://hubs.ly/Q02Gr5ds0
Health Plan Weekly
mmitnetwork.com
-
Join MMIT for the Strategies for Early Access Planning webinar on July 25th: https://ow.ly/ox8G50SyiLG. Learn how pharmaceutical companies begin pre-launch planning much earlier in the product life cycle as market access challenges grow.
-
-
New in this week's Radar on Drug Benefits: Uptake of Humira biosimilars flattens, why payers haven't picked up Blue Shield of California's PBM unbundling model, provider concerns over white bagging mount, and more top stories. https://hubs.ly/Q02GfSY70 #Pipeline2Patient Norstella
Radar on Drug Benefits
mmitnetwork.com
-
Despite its cost, Wegovy is currently covered at 54% across all channels, according to MMIT’s payer policy and restriction data. https://ow.ly/FpRm50SyXwm MMIT’s Autumn Bowman looks at coverage trends in this high-growth market.
-
-
In this Q&A, MMIT's Andrew Rouff shares insights on payer reactions to drug shortages, the proposed Medicare drug shortage prevention program, and how pharma companies can anticipate utilization. https://ow.ly/5PWN50SrfEw
-
-
What can pharma companies learn about the competitive landscape well before launch? Register to learn how and why manufacturers benefit from early market research. Reserve your seat: https://ow.ly/a5U550SyhK0 This webinar details how and why manufacturers benefit from early market research. Client use cases will show how planning for potential access scenarios leads to greater utilization at launch. Register today!
-
-
What types of real-world data (RWD) do pharma companies use for life cycle management? This infographic shows the percentage of manufacturers relying on RWD: https://ow.ly/tnrp50StOr2. Explore the use cases from Phase I to competitor entry in this infographic.
-
